Pediatric Dermatology: Diagnostic Challenges. Part 6

Micronized isotretinoin is currently beingness evaluated by
the US Food and Drug Medication, but it has not been approved at this
time.
John S.
Strauss the Elder, MD, Body of Iowa, Iowa City, discussed the new style
of isotretinoin.
This chemical compound provides some advantages over the form currently
available.
In fact, micronized isotretinoin need not be taken with food to assure
adequate preoccupancy and may be given as a digit daily dose.
These factors may improve conformity.

A clinical experiment
comparing the efficacy of the 2 formulations over 0-20 weeks showed
nearly identical results in papulopustular and nodular acne.
Adverse effects were essentially identical, although there were
slightly fewer and less intense mucocutaneous adverse events in the
micronized isotretinoin grouping.
Science lab abnormalities were not significantly different.
If approved, the new micronized isotretinoin will be recommended at a dose of at 0.4 mg/kg per day.

This is a part of article Pediatric Dermatology: Diagnostic Challenges. Part 6 Taken from "Acne Isotretinoin Accutane" Information Blog